Matters Concerning Controlling Shareholders (Affiliated Companies)
Filed with TSE · · 2 pages · English
Hyogo, Japan – June 23, 2026 – JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”) announces, with respect to MEDIPAL HOLDINGS CORPORATION, our affiliated company concerning the controlling shareholders that are described below. 1. Trade names of the parent company, controlling shareholders (excluding the parent company) or other affiliated companies (As of March 31, 2026) 2. The positioning of the li
JCR Pharmaceuticals Co., Ltd. on 6ix
Earlier from JCR Pharmaceuticals
- JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer’s Disease, Enabled by J-Brain Cargo® Technology Platform
- JCR Pharmaceuticals’ Research Presentations at WORLDSymposium™ 2026 Showcase Data from Its Investigational Treatments for Lysosomal Storage Disorders
- FY2025 Third Quarter Results Briefing Session - Script（1,742KB）
- FY2025-Q3 Financial Report (Oct. 1-Dec. 31, 2025)（390KB）
- JCR Pharmaceuticals to Present at the 22nd Annual WORLDSymposium™ 2026
Later from JCR Pharmaceuticals
- JCR Pharmaceuticals Announces Development Plan in Japan for Givinostat for Duchenne Muscular Dystrophy
- JCR Pharmaceuticals Receives Marketing Authorization in the United Arab Emirates for IZCARGO™, a Blood-Brain Barrier-Penetrating Enzyme Replacement Therapy for Hunter Syndrome
- Notice Regarding the Completion of Payment for the Disposition of Treasury Stock as Restricted Stock Compensation
- FY2026 First Quarter Results Briefing Session Material
- JCR Pharmaceuticals Receives Orphan Drug Designation from the Ministry of Health, Labour and Welfare of Japan for Givinostat for Duchenne Muscular Dystrophy
Follow JCR Pharmaceuticals into a list and get an email when it puts out news.
Follow JCR Pharmaceuticals